Physician profile
Johnathon Eric Downing
NPI 1285990671
$1,972.95
in general payments reported to CMS, 2019-2025
26 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.00 · 2020: $43.36 · 2021: $129 · 2022: $355 · 2023: $437 · 2024: $309 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $352.31 | 2025 | |
| Alcon Vision LLC | $230.94 | 2021-2025 | Argos, Clareon, Rocklatan |
| Abbvie INC. | $212.86 | 2022-2023 | Durysta |
| Rxsight INC | $177.37 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| New World Medical,INC. | $140.97 | 2022 | |
| Harrow Eye, LLC | $115.83 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $106.98 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $93.17 | 2021-2022 | |
| Glaukos Corporation | $86.77 | 2022-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Bausch & Lomb Americas INC. | $64.41 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sight Sciences, INC. | $43.36 | 2020 | |
| Horizon Therapeutics Plc | $42.58 | 2023 | Tepezza |
| Astellas Pharma US INC | $42.06 | 2023-2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $38.16 | 2021 | |
| Thea Pharma INC. | $37.62 | 2022-2023 | Iyuzeh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36.55 | 2024 | Eylea Hd |
| Amgen INC. | $29.97 | 2025 | Tepezza |
| Dompe US, INC. | $27.06 | 2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $23.00 | 2019 | |
| Ocular Therapeutix, INC. | $21.05 | 2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $18.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.56 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $14.39 | 2025 | Xdemvy |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathon Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.